Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06178770 · ClinicalTrials.gov registry record
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 414
- Enrollment target
NCT06178770 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 414 participants.
The verdict
NCT06178770 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 414 participants
- Enrollment target
Study Summary
This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor (VEGF) and had ≥3 brolucizumab injections with no other anti-VEGF in the first 12 months (360 days) and 18 months (540 days) of follow-up respectively; and the 12-month and 18-month alternating (ALT) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had ≥2 brolucizumab injections and ≥1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up, respectively.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2022-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06178770
The ClinicalTrials.gov registry entry for NCT06178770 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06178770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06178770 about?
NCT06178770 is a clinical study titled "Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up". This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endo...
What is the current status of trial NCT06178770?
This trial is currently completed. The enrollment target is 414 participants. The study started on 2021-12-01. Estimated completion is 2022-12-12.
Who is sponsoring clinical trial NCT06178770?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.